priors.science/reviews/cystic-fibrosis-treatment

Cystic Fibrosis Treatment

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked

5 May 2026latest evidence review

Weeklyre-scored against new papers

8 Established · 7 Likely · 1 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableElexacaftor/tezacaftor/ivacaftor (ETI) triple therapy produces large, sustained improvements in FEV1 and reduces pulmonary exacerbations in people with CF carrying at least one F508del CFTR mutation.Established95%—

StableIvacaftor monotherapy produces sustained improvements in FEV1, sweat chloride, and quality of life in CF patients with gating mutations (class III, particularly G551D).Established93%—

StableETI triple therapy significantly reduces sweat chloride concentration and improves nutritional status (BMI, weight gain) in F508del-carrying CF patients.Established92%—

StableElexacaftor/tezacaftor/ivacaftor substantially reduces the frequency of pulmonary exacerbations and hospitalisation rates compared with pre-ETI standard of care.Established92%—

StableInhaled DNase (dornase alfa) reduces sputum viscosity and decreases pulmonary exacerbation frequency and hospitalisation rates in CF.Established87%—

StableInhaled hypertonic saline improves mucociliary clearance and reduces pulmonary exacerbation frequency in CF.Established85%—

StableEarly aggressive antibiotic eradication of Pseudomonas aeruginosa at first isolation reduces chronic infection rates and improves long-term pulmonary outcomes in CF.Established85%—

StableLumacaftor/ivacaftor (dual combination) produces modest FEV1 improvement in F508del homozygous CF patients but is substantially less effective than ETI triple therapy.Established85%—

StableReal-world effectiveness of ETI approximates clinical trial outcomes and extends to populations underrepresented in pivotal trials, including patients with advanced lung disease.Likely84%—

StableInhaled tobramycin and aztreonam reduce Pseudomonas aeruginosa sputum density and improve FEV1 in chronically infected CF patients.Likely84%—

StableIntravenous antibiotic combinations targeting Pseudomonas aeruginosa are the standard of care for severe CF pulmonary exacerbations requiring hospitalisation.Likely81%—

StableLung clearance index (LCI) is a more sensitive measure of early CF lung disease progression than FEV1 and detects treatment response in patients with preserved spirometry.Likely80%—

StableCFTR modulator therapy (particularly ETI) reduces the incidence and severity of CF-related diabetes by improving CFTR function in pancreatic ductal cells.Likely80%—

StableNext-generation CFTR modulators (vanzacaftor/tezacaftor/deutivacaftor) achieve superior CFTR correction to ETI in in vitro studies and phase 2 clinical data, with potential for once-daily dosing.Likely72%—

StablemRNA and gene therapy approaches targeting CFTR restoration in class I and rare mutation CF patients represent a clinically viable strategy for the ~10% of patients who cannot benefit from current modulators.Uncertain52%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic